UB
RPRX icon

UMB Bank’s Royalty Pharma RPRX Stock Holding History

UMB Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
283
+36
+15% +$1.87K ﹤0.01% 1773
2026
Q1 		$11.8K Buy
247
+22
+10% +$964 ﹤0.01% 1798
2025
Q4 		$8.69K Buy
225
+22
+11% +$839 ﹤0.01% 1867
2025
Q3 		$7.16K Buy
203
+8
+4% +$290 ﹤0.01% 1786
2025
Q2 		$7.03K Buy
195
+45
+30% +$1.49K ﹤0.01% 1722
2025
Q1 		$4.67K Buy
150
+8
+6% +$254 ﹤0.01% 1780
2024
Q4 		$3.62K Buy
+142
New +$3.77K ﹤0.01% 1810
2023
Q2 		– Sell
-50
Closed -$1.8K – 1737
2023
Q1 		$1.8K Sell
50
-351
-88% -$13K ﹤0.01% 1532
2022
Q4 		$16K Hold
401
– – ﹤0.01% 1169
2022
Q3 		$16K Hold
401
– – ﹤0.01% 1185
2022
Q2 		$17K Sell
401
-53
-12% -$2.17K ﹤0.01% 1241
2022
Q1 		$18K Buy
454
+11
+2% +$432 ﹤0.01% 1291
2021
Q4 		$18K Buy
+443
New +$17.2K ﹤0.01% 1309

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UMB Bank's RPRX Position: Q2 2026 in Review

UMB Bank increased its Royalty Pharma (RPRX) stake by 15% in Q2 2026, buying an estimated $1.87K and bringing the position to 283 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

UMB Bank first reported a position in RPRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $18K in Q1 2022. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • UMB Bank held 283 shares of Royalty Pharma worth $15.9K as of Q2 2026.
  • UMB Bank bought 36 Royalty Pharma shares in Q2 2026, an estimated $1.87K.
  • Royalty Pharma made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1773 holding.
  • UMB Bank first reported a position in Royalty Pharma in Q4 2021 and has held it in 13 quarters since.
  • UMB Bank's Royalty Pharma position peaked at $18K in Q1 2022.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.